Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

2.319 +0.029 (+1.26%)
Streaming Delayed Price Updated: 1:45 PM EDT, Apr 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Corporate Update, FY 2022 Results
Via Investor Brand Network
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
From VistaGen Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For June 23, 2022
Companies Reporting Before The Bell • Jerash Holdings (US) (NASDAQ:JRSH) is projected to report quarterly earnings at $0.07 per share on revenue of $30.14 million. 
Via Benzinga
Week in Review: VectorBuilder Plans $500 Million Gene Therapy Delivery CDMO in Guangzhou
Deals, financings, trials and approvals in biotech in China this week. 
Via Talk Markets
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Completes PH94B PALISADE-1 Phase 3 Clinical Study for Acute Treatment of SAD
Via Investor Brand Network
Earnings Preview For VistaGen Therapeutics
VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Thursday, 2022-06-23. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Schedules Webcast to Announce FY 2022 Results
Via Investor Brand Network
VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
From VistaGen Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 269 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 422 stocks made new 52-week lows. 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Present Clinical Trial Abstract at ASCP Annual Meeting
Via Investor Brand Network
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Top Investor Conferences
Via Investor Brand Network
VistaGen to Participate in Upcoming June Investor Conferences
From VistaGen Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 540 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 149 companies reached new 52-week lows. 
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains. 
Via InvestorPlace
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Names New Chief Legal Officer
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
VistaGen Appoints Reid Adler as Chief Legal Officer
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Slated to Report Preclinical Data on Lead Candidate at Upcoming Scientific Congresses
Via Investor Brand Network
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), AffaMed Announce Substantial Progress Toward Initiating PALISADE Global Trial
Via Investor Brand Network
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
From VistaGen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Maxim Group 2022 Virtual Growth Conference
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Monday
On Monday, 524 stocks hit new 52-week lows. Areas of Interest About Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was Taiwan... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 671 companies achieved new lows for the year. Points of Interest From Today's 52-Week Lows: Alibaba Group Holding (NYSE:BABA) was the largest firm by... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: The company with the largest market cap to... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.